We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Evaluating Renal Cell Carcinoma Risk Factors (MICRA)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00927043
First Posted: June 24, 2009
Last Update Posted: November 7, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Pfizer
June 22, 2009
June 24, 2009
November 7, 2011
May 2009
September 2011   (Final data collection date for primary outcome measure)
Progression-free survival [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT00927043 on ClinicalTrials.gov Archive Site
  • Response rate. [ Time Frame: 12 months ]
  • Overall survival. [ Time Frame: 12 months ]
  • Response rate [ Time Frame: 12 months ]
  • Overall survival [ Time Frame: 12 months ]
Not Provided
Not Provided
 
Study Evaluating Renal Cell Carcinoma Risk Factors
Prospective, Multicenter, Epidemiological Study To Determine The Clinical, Molecular And Genetic Factors Associated To The Prognosis Of Patients With Advanced Renal Cell Carcinoma
This is an epidemiological, prospective, multicenter study designed to identify the pre-treatment clinical, molecular and genetic prognostic factors associated with progression free survival in patients naïve to renal cell carcinoma (RCC) treatment.
invitation to volunteer
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
Whole blood
Non-Probability Sample
Treatment naive patients with proven advanced RCC
Carcinoma, Renal Cell
Other: Epidemiological study according to clinical practice
Epidemiological study according to clinical practice.
1
Intervention: Other: Epidemiological study according to clinical practice
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
145
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Treatment naïve patients with proven advanced RCC will be evaluated. (Except surgery or radiotherapy)
  • =18 years, any gender.
  • Patients with advanced Renal Cell Carcinoma and treatment naïve.

Exclusion Criteria:

  • Patients who have already initiated any kind of specific therapy for the treatment of RCC.2.
  • Patients with other neoplasias different from RCC (current or past).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Spain
 
 
NCT00927043
3066K1-4433
B1771010
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
November 2011